Annals of Hematology

Papers
(The H4-Index of Annals of Hematology is 22. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)
ArticleCitations
Refractory hepatosplenic T-cell lymphoma was successfully treated with salvage allogeneic hematopoietic stem cell transplantation combined with enhanced myeloablative preconditioning71
A case of acute promyelocytic leukemia with pericardial effusion successfully managed with colchicine during ATO administration51
Concomitant multiple sclerosis and polycythemia vera successfully treated with glatiramer acetate50
Trimethoprim-sulfamethoxazole prevents interstitial pneumonitis in B-cell lymphoma patients receiving chemotherapy: a propensity score matching analysis49
Efficacy and safety of olverembatinib as maintenance therapy after allogeneic hematopoietic cell transplantation in Philadelphia chromosome–positive acute lymphoblastic leukemia47
Correction to: Hemophagocytic lymphohistiocytosis in HIV-associated lymphoproliferative disorders47
Impact of race and ethnicity on outcomes after autologous stem cell transplantation for patients with newly diagnosed multiple myeloma44
Sufficient vitamin D is favorable for children with persistent and chronic immune thrombocytopenia44
Clonal evolution analysis of a rare acute promyelocytic leukemia patient transforming from essential thrombocythemia40
CAG (cytarabine, aclarubicin and granulocyte colony-stimulating factor) regimen for core binding factor acute myeloid leukaemia with measurable residual disease36
Risk factors and outcome of Stenotrophomonas maltophilia infection after allogeneic hematopoietic stem cell transplantation: JSTCT, Transplant Complications Working Group34
Effectiveness of prophylactic antiviral therapy in reducing HBV reactivation for HBsAg-positive recipients following allogeneic hematopoietic stem cell transplantation: a multi-institutional experienc32
Treatment of EPOR-rearranged acute lymphoblastic leukemia with ruxolitinib: case reports and review of the literature30
Refractory pure red cell aplasia associated with T-cell large granular lymphocyte leukemia treated by ruxolitinib30
Real-life use of mTOR inhibitor-based therapy in adults with autoimmune cytopenia highlights strong efficacy in relapsing/refractory multi-lineage autoimmune cytopenia29
Radiotherapy alone with curative intent in a case of limited-stage extranodal NK/T-cell lymphoma nasal type: a case report and review of the literature29
Nomogram for predicting survival of patients with diffuse large B-cell lymphoma25
Advances in the ocular complications after hematopoietic stem cell transplantation25
Total thrombus formation analysis in patients with myeloid neoplasia and thrombocytopenia24
Predictive factors of romiplostim response in patients with refractory aplastic anemia: data from two clinical trials23
Circulating tumor DNA assisting lymphoma genetic feature profiling and identification22
Health-related quality of life with daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible patients with newly diagnosed multipl22
Absence of blood donors’ anti-SARS-CoV-2 antibodies in pre-storage leukoreduced red blood cell units indicates no role of passive immunity for blood recipients22
0.2409188747406